Effects of remifentanil anesthesia on cardiac electrophysiologic properties in children undergoing catheter ablation of supraventricular tachycardia.
Remifentanil is commonly used during anesthesia in pediatric electrophysiologic studies (EPS). The purpose of this study is to determine the effects of remifentanil on the cardiac electrophysiologic properties of children undergoing ablation of supraventricular tachycardia (SVT). A prospective study was performed in patients undergoing EPS before ablation of SVT. Each patient received two different anesthetic protocols: protocol 1 = propofol (200 mcg/kg/min) and protocol 2 = propofol (120 mcg/kg/min) plus remifentanil (0.3 mcg/kg/min). EPS data were measured during the steady state of each protocol. Paired Student t test was performed for analysis of continuous data. All p values <0.05 were considered statistically significant. Fifteen patients were enrolled between April 2005 and January 2006. The mean age was 13.3 ± 2.9 years (range 6.7 to 17.7). Seven patients had atrioventricular (AV) nodal re-entry tachycardia; 5 patients had Wolff-Parkinson-White syndrome; 2 patients had a concealed accessory pathway; and 1 patient was not inducible. Of the 14 patients who underwent ablation, 13 (93%) achieved successful. The baseline sinus cycle length extended from 884 ± 141 ms during protocol 1 to 980 ± 165 ms during protocol 2 (p = 0.01), and the Wenckebach cycle length lengthened from 377 ± 96 ms to 406 ± 109 ms (p = 0.01). No other variables measured (atrial-His (AH) and His-ventricular (HV) interval, atrioventricular node (AVN), and atrial, ventricular, and accessory pathway effective refractory periods) changed significantly between the two different protocols. In pediatric patients undergoing EPS before ablation of SVT, remifentanil appears to slow both sinus and AV nodal function. These effects should be taken into consideration when performing EPS.
Niksch
Alisa
A
Pediatric Arrhythmia Service, The Heart Institute for Children, Oak Lawn, IL, USA.
Liberman
Leonardo
L
Clapcich
Anthony
A
Schwarzenberger
Johanna C
JC
Silver
Eric S
ES
Pass
Robert H
RH
D000293:Adolescent; D018686:Anesthetics, Intravenous / Q000494:pharmacology*; D054849:Cardiac Electrophysiology; D017115:Catheter Ablation; D002648:Child; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects*; D006801:Humans; D008297:Male; D010880:Piperidines / Q000494:pharmacology*; D000077208:Remifentanil; D013617:Tachycardia, Supraventricular / Q000601:surgery
D018686:Anesthetics, Intravenous; D010880:Piperidines; D000077208:Remifentanil
Pacing Clin Electrophysiol. 1999 Sep;22(9):1358-64
10527017
Pediatr Ann. 1991 Jul;20(7):386, 388-92
1923646
J Clin Anesth. 1995 Nov;7(7):558-63
8652166
Anesthesiology. 1995 Apr;82(4):884-7
7717559
Acta Anaesthesiol Scand. 2002 Apr;46(4):355-60
11952432
Pacing Clin Electrophysiol. 2002 Jun;25(6):1000-17
12137336
Anesthesiology. 1997 Oct;87(4):1019-20
9357922
Anesthesiology. 2002 Jun;96(6):1386-94
12170051
J Cardiothorac Vasc Anesth. 2001 Dec;15(6):736-9
11748523
Paediatr Anaesth. 2005 May;15(5):397-401
15828991
J Am Coll Cardiol. 1991 Jun;17(7):1613-20
2033194
Anesthesiology. 1999 Jan;90(1):60-5
9915313
Minerva Anestesiol. 2003 Sep;69(9):673-7, 677-9
14564237